Literature DB >> 18406473

Early blood-brain barrier permeability in cerebella of PLSJL mice immunized with myelin basic protein.

Sergei Spitsin1, Carla Portocarrero, Timothy W Phares, Rhonda B Kean, Christine M Brimer, Hilary Koprowski, D Craig Hooper.   

Abstract

The blood-brain barrier (BBB) is dramatically but transiently compromised in the cerebella of myelin basic protein immunized mice at least 1 week prior to the development of the paralytic phase of experimental allergic encephalomyelitis (EAE). Treatment of mice with the peroxynitrite-dependent radical scavenger uric acid (UA) during the first week after immunization blocks the early increase in cerebellar BBB permeability and the subsequent development of clinical signs of EAE. These results indicate that the early loss of BBB integrity in the cerebellum is likely to be a necessary step in the development of paralytic EAE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406473      PMCID: PMC2490597          DOI: 10.1016/j.jneuroim.2008.02.004

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  28 in total

1.  Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement.

Authors:  Diane M Muller; Michael P Pender; Judith M Greer
Journal:  J Neuroimmunol       Date:  2005-01-07       Impact factor: 3.478

Review 2.  Cytokines in multiple sclerosis: from bench to bedside.

Authors:  Jaime Imitola; Tanuja Chitnis; Samia J Khoury
Journal:  Pharmacol Ther       Date:  2005-01-11       Impact factor: 12.310

3.  Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli.

Authors:  Christine Silwedel; Carola Förster
Journal:  J Neuroimmunol       Date:  2006-08-01       Impact factor: 3.478

4.  Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system.

Authors:  Timothy W Phares; Rhonda B Kean; Tatiana Mikheeva; D Craig Hooper
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

5.  Region-specific regulation of inflammation and pathogenesis in experimental autoimmune encephalomyelitis.

Authors:  Angela S Archambault; Julia Sim; Erin E McCandless; Robyn S Klein; John H Russell
Journal:  J Neuroimmunol       Date:  2006-10-09       Impact factor: 3.478

6.  CNS-irrelevant T-cells enter the brain, cause blood-brain barrier disruption but no glial pathology.

Authors:  Alina Smorodchenko; Jens Wuerfel; Elena E Pohl; Johannes Vogt; Eva Tysiak; Robert Glumm; Sven Hendrix; Robert Nitsch; Frauke Zipp; Carmen Infante-Duarte
Journal:  Eur J Neurosci       Date:  2007-09       Impact factor: 3.386

7.  Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis.

Authors:  D C Hooper; G S Scott; A Zborek; T Mikheeva; R B Kean; H Koprowski; S V Spitsin
Journal:  FASEB J       Date:  2000-04       Impact factor: 5.191

8.  Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models.

Authors:  Marzena J Fabis; Gwen S Scott; Rhonda B Kean; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

9.  Peroxynitrite formation within the central nervous system in active multiple sclerosis.

Authors:  A H Cross; P T Manning; R M Keeling; R E Schmidt; T P Misko
Journal:  J Neuroimmunol       Date:  1998-08-01       Impact factor: 3.478

10.  Cerebellar susceptibility to experimental autoimmune encephalomyelitis in SJL/J mice: potential interaction of immunology with vascular anatomy.

Authors:  James R Tonra
Journal:  Cerebellum       Date:  2002 Jan-Mar       Impact factor: 3.847

View more
  3 in total

1.  The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS.

Authors:  Wei Cui; Zaijun Zhang; Wenming Li; Shengquan Hu; Shinghung Mak; Huan Zhang; Renwen Han; Shuai Yuan; Sai Li; Fei Sa; Daping Xu; Zhixiu Lin; Zhong Zuo; Jianhui Rong; Edmond Dik-Lung Ma; Tony Chunglit Choi; Simon My Lee; Yifan Han
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

2.  The treatment of multiple sclerosis with inosine.

Authors:  Clyde E Markowitz; Sergei Spitsin; Vanessa Zimmerman; Dina Jacobs; Jayaram K Udupa; D Craig Hooper; Hilary Koprowski
Journal:  J Altern Complement Med       Date:  2009-06       Impact factor: 2.579

3.  Studying the blood-brain barrier will provide new insights into neurodegeneration - Yes.

Authors:  Wouter W Kamphuis; Helga E De Vries
Journal:  Mult Scler       Date:  2018-03-05       Impact factor: 6.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.